Back to Search Start Over

Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry

Authors :
Claire de Moreuil
Olivier Aumaître
Pascal Godmer
Alexis Régent
François Maurier
Christian Pagnoux
Luc Mouthon
Bernard Bonnotte
Xavier Puéchal
Michele Iudici
Chahéra Khouatra
Noémie Jourde-Chiche
Marc Ruivard
François Lifermann
Benjamin Terrier
Claire Blanchard-Delaunay
Antoine Néel
Eric Hachulla
Pascal Cohen
Delphine S. Courvoisier
Thomas Le Gallou
Jean-François Viallard
Alain Le Quellec
Achille Aouba
Loïc Guillevin
Thomas Quemeneur
Alexandre Karras
Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN)
Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Source :
Rheumatology, Rheumatology, 2022, 61 (6), pp.2464-2471. ⟨10.1093/rheumatology/keab719⟩, Rheumatology (2021)
Publication Year :
2022
Publisher :
HAL CCSD, 2022.

Abstract

Objective To describe the main features at diagnosis and evolution over time of patients with localized granulomatosis with polyangiitis (L-GPA) compared with those of systemic GPA (S-GPA). Methods EULAR definitions of L-GPA, i.e. upper and/or lower respiratory tract involvement, and S-GPA were applied to patients from the French Vasculitis Study Group Registry. L-GPA and S-GPA patients’ characteristics at diagnosis and long-term outcomes were analysed and compared. Results Among the 795 Registry patients, 79 (10%) had L-GPA. Their main clinical manifestations were rhinitis, lung nodules, sinusitis and otitis. L-GPA vs S-GPA patients at diagnosis, respectively, were younger, more frequently had saddle nose deformity or subglottic stenosis and were less often PR3-ANCA–positive. L-GPA vs S-GPA induction therapy less frequently included CYC but more often a combination of MTX and glucocorticoids; 64% of MTX-treated patients experienced disease progression within 18 months post-diagnosis. L- and S-GPA patients’ estimated relapse-free–survival probabilities, relapse rates and refractory disease rates at each time point were comparable, but L-GPA patients had more frequent ENT and lung relapses, and higher overall survival rates (P Conclusions The relapse risks of L-GPA and S-GPA were similar, but relapse patterns differed and L-GPA overall survival rate was higher. About one-quarter of L-GPA patients developed S-GPA over time, but without end-stage organ involvement.

Details

Language :
English
ISSN :
14620324 and 14602172
Database :
OpenAIRE
Journal :
Rheumatology, Rheumatology, 2022, 61 (6), pp.2464-2471. ⟨10.1093/rheumatology/keab719⟩, Rheumatology (2021)
Accession number :
edsair.doi.dedup.....cceace6e3041ab0ec76da5e03bbec5c5
Full Text :
https://doi.org/10.1093/rheumatology/keab719⟩